You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Calidi Biotherapeutics Names Heehyoung Lee to Board of Directors
Login
Username:

Password:


Related Headlines

Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease

Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer

Labcorp, Charles River and FDA collaborate on advancing preclinical methods for evaluating drug abuse potential

HUYABIO International reports positive Phase 3 trial results for HBI-8000 and nivolumab combination

Harbour BioMed's batoclimab injection receives Chinese regulatory approval to treat generalised myasthenia gravis

NFL Biosciences secures regulatory approval to launch Phase 2 trial of NFL-102

ProBio's Nanjing biologics manufacturing facility completes Chinese regulatory pre-approval inspection

Lynch Regenerative Medicine's Phase IIb clinical trial of rhPDGF-BB injection cleared by FDA

European Commission approves Novartis' Cosentyx for polymyalgia rheumatica

GSK wins US FDA approval for chronic hepatitis B treatment Hibsago

Summit Therapeutics and ECOG-ACRIN launch Phase II/III trial collaboration for biliary tract cancer

RxMP Therapeutics secures DARPA contract worth up to USD10.7m

TNutra launches NeuraLegend brain health supplements

Health Canada approves AbbVie psoriasis treatment for children

WuXi AppTec recognised in Frost & Sullivan's Global Company of the Year awards for Tenth Consecutive Year

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026